CN109364157A - 用于治疗积水症的中药组合物及其制备方法与应用 - Google Patents
用于治疗积水症的中药组合物及其制备方法与应用 Download PDFInfo
- Publication number
- CN109364157A CN109364157A CN201811514368.4A CN201811514368A CN109364157A CN 109364157 A CN109364157 A CN 109364157A CN 201811514368 A CN201811514368 A CN 201811514368A CN 109364157 A CN109364157 A CN 109364157A
- Authority
- CN
- China
- Prior art keywords
- weight
- parts
- disease
- vinegar
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 117
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 104
- 201000010099 disease Diseases 0.000 title claims abstract description 86
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 206010003445 Ascites Diseases 0.000 claims abstract description 53
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 241000221079 Euphorbia <genus> Species 0.000 claims abstract description 39
- ZOMNIUBKTOKEHS-UHFFFAOYSA-L dimercury dichloride Chemical compound Cl[Hg][Hg]Cl ZOMNIUBKTOKEHS-UHFFFAOYSA-L 0.000 claims abstract description 39
- 210000001015 abdomen Anatomy 0.000 claims abstract description 34
- 206010030113 Oedema Diseases 0.000 claims abstract description 33
- 241001263989 Wikstroemia Species 0.000 claims abstract description 29
- 206010047700 Vomiting Diseases 0.000 claims abstract description 28
- 230000008673 vomiting Effects 0.000 claims abstract description 28
- 206010000060 Abdominal distension Diseases 0.000 claims abstract description 27
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims abstract description 25
- 239000002994 raw material Substances 0.000 claims abstract description 25
- 241000254173 Coleoptera Species 0.000 claims abstract description 24
- 241000241125 Gryllotalpa gryllotalpa Species 0.000 claims abstract description 24
- 210000003608 fece Anatomy 0.000 claims abstract description 24
- 235000004338 Syringa vulgaris Nutrition 0.000 claims abstract description 23
- 210000000582 semen Anatomy 0.000 claims abstract description 23
- 208000037157 Azotemia Diseases 0.000 claims abstract description 21
- 208000009852 uremia Diseases 0.000 claims abstract description 21
- 210000000952 spleen Anatomy 0.000 claims abstract description 20
- 206010048612 Hydrothorax Diseases 0.000 claims abstract description 19
- 244000046052 Phaseolus vulgaris Species 0.000 claims abstract description 19
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims abstract description 19
- 229940075397 calomel Drugs 0.000 claims abstract description 18
- 238000009825 accumulation Methods 0.000 claims abstract description 16
- 241000269417 Bufo Species 0.000 claims abstract description 15
- 208000003906 hydrocephalus Diseases 0.000 claims abstract description 15
- 230000008961 swelling Effects 0.000 claims abstract description 15
- 238000001631 haemodialysis Methods 0.000 claims abstract description 14
- 230000000322 hemodialysis Effects 0.000 claims abstract description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 10
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- 230000004064 dysfunction Effects 0.000 claims abstract description 8
- 230000002996 emotional effect Effects 0.000 claims abstract description 8
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 7
- 230000007882 cirrhosis Effects 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 94
- 239000000052 vinegar Substances 0.000 claims description 73
- 235000021419 vinegar Nutrition 0.000 claims description 73
- 230000008569 process Effects 0.000 claims description 72
- 239000000843 powder Substances 0.000 claims description 65
- 210000004369 blood Anatomy 0.000 claims description 31
- 239000008280 blood Substances 0.000 claims description 31
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 241001104043 Syringa Species 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 22
- 206010062717 Increased upper airway secretion Diseases 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 21
- 208000026435 phlegm Diseases 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 18
- 244000107975 Strychnos nux-vomica Species 0.000 claims description 15
- 235000015099 wheat brans Nutrition 0.000 claims description 15
- 239000012535 impurity Substances 0.000 claims description 14
- 210000004185 liver Anatomy 0.000 claims description 13
- 210000002700 urine Anatomy 0.000 claims description 12
- 239000004576 sand Substances 0.000 claims description 10
- 238000007789 sealing Methods 0.000 claims description 10
- 210000001835 viscera Anatomy 0.000 claims description 10
- 241000196324 Embryophyta Species 0.000 claims description 8
- 241000628997 Flos Species 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 8
- 230000008025 crystallization Effects 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000014018 liver neoplasm Diseases 0.000 claims description 8
- 210000003141 lower extremity Anatomy 0.000 claims description 8
- 239000002689 soil Substances 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 238000002386 leaching Methods 0.000 claims description 7
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 6
- 239000000571 coke Substances 0.000 claims description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 239000003610 charcoal Substances 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 238000002224 dissection Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000010985 leather Substances 0.000 claims description 5
- 208000008423 pleurisy Diseases 0.000 claims description 5
- 239000008159 sesame oil Substances 0.000 claims description 5
- 235000011803 sesame oil Nutrition 0.000 claims description 5
- PANBYUAFMMOFOV-UHFFFAOYSA-N sodium;sulfuric acid Chemical compound [Na].OS(O)(=O)=O PANBYUAFMMOFOV-UHFFFAOYSA-N 0.000 claims description 5
- 241000521257 Hydrops Species 0.000 claims description 4
- 239000007832 Na2SO4 Substances 0.000 claims description 4
- 235000013339 cereals Nutrition 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 4
- 210000003462 vein Anatomy 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 3
- 208000008765 Sciatica Diseases 0.000 claims description 3
- 208000007536 Thrombosis Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 210000000281 joint capsule Anatomy 0.000 claims description 3
- 201000003453 lung abscess Diseases 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims 1
- 239000007940 sugar coated tablet Substances 0.000 claims 1
- 208000004880 Polyuria Diseases 0.000 abstract description 21
- 230000035619 diuresis Effects 0.000 abstract description 19
- 230000001093 anti-cancer Effects 0.000 abstract description 11
- 206010016766 flatulence Diseases 0.000 abstract description 10
- 206010011224 Cough Diseases 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 9
- 208000030852 Parasitic disease Diseases 0.000 abstract description 8
- 239000003053 toxin Substances 0.000 abstract description 7
- 231100000765 toxin Toxicity 0.000 abstract description 7
- 208000011580 syndromic disease Diseases 0.000 abstract description 6
- 208000006673 asthma Diseases 0.000 abstract description 4
- 201000006549 dyspepsia Diseases 0.000 abstract description 4
- 241000050051 Chelone glabra Species 0.000 abstract description 3
- 230000001151 other effect Effects 0.000 abstract description 3
- 244000297179 Syringa vulgaris Species 0.000 abstract 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 21
- 229910052709 silver Inorganic materials 0.000 description 21
- 239000004332 silver Substances 0.000 description 21
- 239000007789 gas Substances 0.000 description 18
- 210000004072 lung Anatomy 0.000 description 18
- 210000003516 pericardium Anatomy 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 210000003734 kidney Anatomy 0.000 description 15
- 208000002193 Pain Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 230000036407 pain Effects 0.000 description 13
- 210000000038 chest Anatomy 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 231100000614 poison Toxicity 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 210000001124 body fluid Anatomy 0.000 description 9
- 239000010839 body fluid Substances 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 210000002683 foot Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000002574 poison Substances 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 201000005202 lung cancer Diseases 0.000 description 7
- 208000020816 lung neoplasm Diseases 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 206010000077 Abdominal mass Diseases 0.000 description 6
- 208000025865 Ulcer Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 244000273928 Zingiber officinale Species 0.000 description 6
- 235000006886 Zingiber officinale Nutrition 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 235000008397 ginger Nutrition 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 231100000397 ulcer Toxicity 0.000 description 6
- 229910001369 Brass Inorganic materials 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 5
- 241000233866 Fungi Species 0.000 description 5
- 239000010951 brass Substances 0.000 description 5
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 208000015817 Infant Nutrition disease Diseases 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 238000001467 acupuncture Methods 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 229940030606 diuretics Drugs 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 210000004731 jugular vein Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000004910 pleural fluid Anatomy 0.000 description 4
- 238000010791 quenching Methods 0.000 description 4
- 230000000171 quenching effect Effects 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000003802 sputum Anatomy 0.000 description 4
- 208000024794 sputum Diseases 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000004243 sweat Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000228212 Aspergillus Species 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 208000002151 Pleural effusion Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000014617 hemorrhoid Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- 210000002417 xiphoid bone Anatomy 0.000 description 3
- 241000186046 Actinomyces Species 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 241001478240 Coccus Species 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 108010034145 Helminth Proteins Proteins 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000004680 Rectal Fistula Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000235342 Saccharomycetes Species 0.000 description 2
- 206010040007 Sense of oppression Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010058679 Skin oedema Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 240000001417 Vigna umbellata Species 0.000 description 2
- 235000011453 Vigna umbellata Nutrition 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 206010002156 anal fistula Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- NNBFNNNWANBMTI-UHFFFAOYSA-M brilliant green Chemical compound OS([O-])(=O)=O.C1=CC(N(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](CC)CC)C=C1 NNBFNNNWANBMTI-UHFFFAOYSA-M 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 201000003146 cystitis Diseases 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 244000000053 intestinal parasite Species 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 208000008494 pericarditis Diseases 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 230000000505 pernicious effect Effects 0.000 description 2
- 210000004224 pleura Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 201000010153 skin papilloma Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 2
- 229960002256 spironolactone Drugs 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 206010044008 tonsillitis Diseases 0.000 description 2
- 210000003905 vulva Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241001504639 Alcedo atthis Species 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 235000010894 Artemisia argyi Nutrition 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091005950 Azurite Proteins 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000034598 Caecitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010063057 Cystitis noninfective Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 101100276976 Drosophila melanogaster Drak gene Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 241001347978 Major minor Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 241001561899 Otomys Species 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 241000223785 Paramecium Species 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 229940122767 Potassium sparing diuretic Drugs 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000588778 Providencia stuartii Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 241000190070 Sarracenia purpurea Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000009961 Shenshuaining Substances 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 208000004387 Typhlitis Diseases 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 208000011279 abdominal lump Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 244000030166 artemisia Species 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 210000003037 cerebral aqueduct Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000024035 chronic otitis media Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229940048368 flamazine Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 238000002309 gasification Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- PQTCMBYFWMFIGM-UHFFFAOYSA-N gold silver Chemical compound [Ag].[Au] PQTCMBYFWMFIGM-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002837 heart atrium Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 235000014659 low sodium diet Nutrition 0.000 description 1
- 235000020905 low-protein-diet Nutrition 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000000349 mediastinal cancer Diseases 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000018280 neoplasm of mediastinum Diseases 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 239000003286 potassium sparing diuretic agent Substances 0.000 description 1
- 229940097241 potassium-sparing diuretic Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001543 purgative effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 201000010727 rectal prolapse Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 201000006409 renal osteodystrophy Diseases 0.000 description 1
- MKELYWOVSPVORM-DTWKUNHWSA-N reposal Chemical compound C([C@@H]1CC[C@@H](C1)C=1)C=1C1(CC)C(=O)NC(=O)NC1=O MKELYWOVSPVORM-DTWKUNHWSA-N 0.000 description 1
- 229960001472 reposal Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- -1 speed Urine Chemical compound 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- JMCKWTQLJNQCTD-UHFFFAOYSA-N spirit blue Chemical compound Cl.C=1C=C(C(=C2C=CC(C=C2)=NC=2C=CC=CC=2)C=2C=CC(NC=3C=CC=CC=3)=CC=2)C=CC=1NC1=CC=CC=C1 JMCKWTQLJNQCTD-UHFFFAOYSA-N 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 210000000798 superior sagittal sinus Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- GWBUNZLLLLDXMD-UHFFFAOYSA-H tricopper;dicarbonate;dihydroxide Chemical compound [OH-].[OH-].[Cu+2].[Cu+2].[Cu+2].[O-]C([O-])=O.[O-]C([O-])=O GWBUNZLLLLDXMD-UHFFFAOYSA-H 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/28—Mercury; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种用于治疗积水症的中药组合物及其制备方法与应用。原料组分包括:赤小豆1~100重量份、大戟1~100重量份、甘遂1~100重量份、芫花1~100重量份、荛花1~100重量份、活大蟾蜍0.01~10重量份、白芥子1~100重量份、蜣螂1~100重量份、蝼蛄1~100重量份、马钱子1~100重量份、轻粉1~100重量份和芒硝1~100重量份。本发明中药组合物选用含有天然活性成分的中药药材,组方配比科学,具有优异的抗癌排毒、肿胀喘满、热寒咳嗽、心胸痞闷、食积、水疾蛊胀、逐水消肿等功效,能够有效用于治疗脑积水症、心包积水症、胸腔积水症、肝硬化腹水症、尿毒症血透腹水症和肾炎气臌胀等症。
Description
技术领域
本发明涉及中草药技术领域,具体涉及一种用于治疗积水症的中药组合物及其制备方法与应用。
背景技术
《黄帝内经素问》黄帝曰;恶症水七例;一曰:结气,治之以散;二曰:血瘕,治之以破;三曰:绝伤,治之以续;四曰:死肌,治之以逐;五曰:鼓胀,治之以鸡矢醴;六曰:开鬼门,洁净府之剂;七曰;血肿,宣布五阳之剂。此外,黄帝曰:夫子言痈疽,何以别之?岐伯曰:营卫稽留于经脉之中,则血泣而不行,不行则卫气从之,从之而不通,壅遏而不得行,故曰大热不止,热胜则肉腐,肉腐则为脓,然不能陷于骨髓,骨髓不为焦枯,五脏不为伤,故命曰痈。岐伯曰:“痈疽原是火毒生,中枢经络气血凝,外因六淫八风感,症积六欲并七情,血证起居多失慎,温病疫邪结化毒,恶核之变营卫过,温热毒邪气血贫,肝掌筋骨阴感染,正气内虚败血生,肝脾大里胃肠塞,心肺壅热为失荣,金火相刑紫斑痛,阴盛败脏气传克,抽搐昏迷下肢肿,热邪炽盛鼻齿衄,骨髓为顺七恶逆,石青银翠削蛊毒,临症恶水须详察,凉药补汗攻应分,善治热寒杂症易,银液唯独灭真菌”。
据统计,全国每年癌症与非恶性肿瘤引起“积水症”有1000万人次以上病患,而现代医学对此显得力所不及。具体地:
西医治疗肝腹水穿刺抽水医技学术措施:1、保钾(螺内酯)和排钾(双氢克尿塞、呋塞米)利尿药;2、补充白蛋白以提高血浆胶体渗透压输注白蛋白后,利尿药的利尿作用是否可更好发挥尿量增加;3、采用重组人生长激素;4、腹水治疗:当大量腹水影响到患者的呼吸或患者腹胀症状重而难以忍受时,西医采取穿刺放腹水治疗,以减轻症状。每次抽取腹水量以1000~3000ml是不道德行为。抽完腹水后可向腹腔内注射多巴胺20mg,可增强利尿效果由于大量多次放腹水可导致蛋白质与电解质的丢失,腹水感染的机会也会随时增加、造成腹水病人雪上加霜;5、采用穿刺放腹水浓缩回输法治疗,即将腹水超滤后将腹水中的蛋白质电解质等物质经颈静脉回输入体内腹水颈静脉回流术是将硅胶管从腹腔内沿腹壁、胸壁下插入到颈静脉内,使腹水引流入颈静脉内;TIPS方法对降低门静脉压力、西医技妄图消退腹水、其副作用会发生不可逆的肝性脑病并发症;6、治疗肝腹水手段:用与腹水无关药(冠心病)静脉滴注川芎嗪每天100~150mg或多巴胺20~40mg西医术妄想增强利尿效果。结论:世界西医历时200多年以来,很难治愈重症肝硬化腹水病人。
世界西医治疗脑积水医技学术措施:1、应用利尿剂,如乙酰唑胺、双氢克尿塞、速尿、甘露醇等;2、经前囟或腰椎反复穿刺放液;3、手术疗法:手术治疗对进行性脑积水,头颅明显增大,且大脑皮质厚度小于1cm者,采取索命手术治疗。手术可分为以下几种:(1)减少脑脊液分泌的手术:脉络丛切除术后的灼烧术;(2)解除脑室梗阻病因手术:如大脑导水管形成术或扩张术,正中孔切开术及颅内占位病变摘除术;(3)脑脊液分流手术:手术目的是建立脑脊液循环通路,解除脑脊液的积蓄,兼用于交通性或非交通脑积水。常用的分流术包括颅内分流和颅外分流,颅内分流有脑室-小脑延髓池引流术、三脑室造瘘术。颅外分流手术有脑室-心房分流术及脑室-腹腔分流术,侧脑室-腹腔、上矢状窦、心房、颈外静脉等分流术。然而,这种索命脑脊液分流手术,随时可引起病人感染生命危险。中国西医历时100多年,很难治愈开脑引流术病人。
世界上西医治疗肺癌胸水医技学术方法:其治疗的原则主要是靠穿刺抽取胸水为主,但临床上发现抽水后往往易反复,而且抽水并不能彻底的消除胸水。临床上在抽取胸水时向胸腔注入一些成瘾性的药物,如保钾利尿剂、排钾保钠、螺内酯、抗癌药、硬化剂、免疫调节药等,直接杀伤癌细胞,减缓肺癌胸水产生,但是此种方法会给患者带来巨大的痛苦,患者往往很难承受。也有部分患者接受外科治疗,在进行肺癌切除术后采用化疗,以达到消除胸水的目的。西医认为手术切除肺癌可减少病人肿瘤的痛苦,抑制肺癌细胞向周围转移及扩散,术后化疗及放疗可继续治疗残存肿瘤及微转移灶,延缓肿瘤复发的时间,防止胸水再生。但是此种治疗方法对患者本身的创伤和副作用特大,多数患者并不能承受如此折磨的肺癌胸水治疗方法。西医科学技术很难治愈胸水且保证永不复发。
世界西医治疗尿毒症血透腹水医技学术措施:1、饮食治疗:低蛋白饮食,避免含氮代谢废物及毒物在体内蓄积;2、治疗高血压:控制高血压,延缓病情的恶化速度,常用药物如下:利尿剂、钙离子拮抗剂、受体阻断剂、受体阻断剂,最后拿出看家、利尿、高血压系列药ACEI,ARB;3、应用钙离子拈抗剂,如心痛定药;4、口服氧化淀粉、尿毒清、肾衰宁、海昆肾喜胶囊等吸附剂、使血尿素氮下降;5、口服无效药:钙剂和维生素口治疗肾性骨病;6、增加铁剂和叶酸的摄入有利改善肾性贫血、西医长期应用促红细胞生成素等无效药;7、最终匝医拿出医枝学术(穿刺抽水)治疗尿毒症腹水病人;8、血液透析:血液透析是将患者的血液与透析液同时引入透析器膜的两侧,通过半透膜清除血液中的代谢废物、纠正电解质和酸碱失衡、并清除体内多余的水份、血液透析可以部分地替代肾脏功能。西医的治尿毒症腹水是独家发明、目前广泛应用的尿毒症主要治疗方法之一;9、腹膜透析应用人体自身的腹膜作为透析膜进行血液净化、将透析液引入患者腹腔、血液中的毒素和多余水分尿液、通过腹膜进入腹腔中的透析液然后排出体外、定时或不断更换腹腔中的透析液、西医想达到净化血液的目的。西医腹膜透析学术,很难治愈尿毒症腹水病人;10、西医认定,独家发明糖尿病、尿毒症是中医的消渴(三消)症;中医只需几剂药就能治愈。三消病因肺燥、胃热、肾虚之别;《丹溪心法》曰:消渴篇;“消渴,养肺、降火、生血为主,分上中下治”;岐黄之术论;消渴,若泄泻,用白术、白芍药炒为末,调服后,却服前药(即诸汁膏)。内伤病退后,燥渴不解,此热在肺经,可用参、芩、甘草少许,生地姜汁调,冷服。或以茶匙挑姜龙香汁与之。虚者可用人参汤。龙诞香0.1g蜂蜜、油菜花粉,可救活一个被西医判处二周内死刑危急尿毒症病人、此乃消渴神药也。上消者,肺也,多饮水而少食,大小便如常;中消者,胃也,多饮水而小便赤黄;下消者,肾也,小便浊淋如膏之状,面黑而瘦。
世界西医治疗心包积水引流医技学术措施:1、药物治疗包括应用激素、抗炎药、抗结核药以及其他病因治疗;2、心包穿刺可减轻症状,可抽取心包内液进行分析,以助于诊断和治疗,但其本身的治疗效果并不确切,这是西医主要的治疗手段;3、手术治疗的目的在于解除已有的或可能发生的心包堵塞,清除心包积液,有可能减少心包积液复发的可能性,防止晚期心包缩窄;4、药物治疗无效的情况下,就实行心包引流及心包切除;5、经剑突下心包引流、操作迅速、造成巨大损伤、术后几天效果无明显改善,肺部并发症巨大,危及重病人、高龄病人,但术后心包积液积水的复发率极高。为减低复发率,西医注意心包切除的范围;6、经剑突下心包引流的方法;西医在70年代始将其称为心包开窗;然而,心包开窗的治疗机制,只是近数年才得以明悉。研究表明:在持续充分引流的基础上,心外膜与心包之间出现纤维粘连,造成心包腔积水难以治理。
基于此,亟需提供一种能够有效治疗积水症的中药组合物,以缓解诸多患者的痛楚。
发明内容
针对现有技术中的缺陷,本发明旨在提供一种用于治疗积水症的中药组合物及其制备方法与应用。本发明治疗积水症的中药组合物选用含有天然活性成分的中药药材,组方配比科学,具有优异的抗癌排毒、肿胀喘满、热寒咳嗽、心胸痞闷、食积、水疾蛊胀、逐水消肿等功效,能够有效用于治疗脑积水症、心包积水症、胸腔积水症、肝硬化腹水症、尿毒症血透腹水症和肾炎气臌胀等症。
为此,本发明提供如下技术方案:
第一方面,本发明提供一种用于治疗积水症的中药组合物,原料组分包括:赤小豆、大戟、甘遂、芫花、荛花、蟾蜍、白芥子、蜣螂、蝼蛄、马钱子、轻粉和芒硝中的一种或多种。
优选地,原料组分按重量份计,包括:赤小豆1~100重量份、大戟1~100重量份、甘遂1~100重量份、芫花1~100重量份、荛花1~100重量份、蟾蜍0.01~10重量份、白芥子1~100重量份、蜣螂1~100重量份、蝼蛄1~100重量份、马钱子1~100重量份、轻粉1~100重量份和芒硝1~100重量份。
优选地,由下述原料制备而成:赤小豆20~80重量份、大戟20~60重量份、甘遂10~50重量份、芫花10~50重量份、荛花20~60重量份、蟾蜍1/3~2/3重量份、白芥子40~70重量份、蜣螂10~40重量份、蝼蛄10~40重量份、马钱子5~30重量份、轻粉5~30重量份和芒硝10~50重量份。
优选地,轻粉选用氯化亚汞结晶;芒硝的主要成分为含水硫酸钠,且具体为Na2SO4·10H2O;蟾蜍选用活大蟾蜍。
优选地,中药组合物呈胶囊粒或糖衣片状;更优选地,胶囊粒的含量为0.35g;糖衣片的含量为0.5g。
申请人经过创造性劳动后发现:将大戟、芫花、甘遂、赤小豆配伍,峻下积滞,逐水消肿,豁痰利咽、寒积便秘,乳食停滞,下腹水肿,二便不通,喉风,喉痹。破噎膈,症瘕积聚、水肿胀满,留饮,结胸,痢痫,泻水逐饮,解毒杀虫。利水通便,瘰疬,痈肿恶疮。胸腹积水,痰饮积聚,气逆喘咳,泻十二种水疾,心腹坚满,下水,去痰水,皮肤浮肿腹满,喘急,不能安卧攻逐心脑水、脘腹经隧之水、化痰逐饮;散结消肿。遂水通便,专逐中焦水、逐水除湿,和血排脓,消肿解毒、大鼠腹腔注射氯化钠溶液造成实验性腹水,口服大戟煎剂或酒精浸液,都有利尿作用为主君药。
大蟾蜍、荛花、蝼蛄:消积,破瘀,行水,解毒、食滞胀满,臌胀,肿毒,痔瘘,破症瘕积聚,去水,下三虫。泻水饮,留饮,咳逆上气,水肿,症瘕痃癖。使气畅水行;破症结,行水湿,化毒,杀虫,定痛。疔疮,发背,阴疽瘰疬,恶疮,症瘕癖积,肾炎气臌胀,水肿,小儿疳积,慢性气管炎、恶疮疽。荡涤泻下为辅。
蜣螂:定惊,破瘀,通二便,恶疮症瘕、攻毒、癫狂,症瘕,噎膈反胃,腹胀便结,疳积,血痢,痔漏,疔肿,恶疮。主辅相配,使水热实邪从二便分消下泄。再以炙马前子;排毒抗癌、通络强筋、散结止痛、散血热,子宫颈癌糜烂,结核病恶疮。癌症痈疽失荣肿痛。通络散结消瘤。重症肌无力症、嗜血流感杆菌。消痞块肿毒、抗癌抗菌、行气攻毒;癥瘕积聚。
轻粉:堇色毛癣菌、许兰氏黄癣菌、奥杜盎氏小芽胞癣菌、红色表皮癣菌、星形奴卡氏菌等真菌均有抑制灭菌作用。痰涎积滞,水肿膨胀,二便不利、逐水通便、痰涎积滞,水肿膨胀共为佐使。白芥子:化痰逐饮;散结消肿。咳喘痰多;胸满胁痛;肢体麻木;关节肿痛;湿痰流注;阴疽肿毒。
芒硝;泻热,润燥,软坚;实热积滞,腹胀便秘,停痰积聚,主五脏积聚,久热胃闭,除邪气,破留血,腹中痰实结搏,通经脉,泻利大小便。诸圣药合用,共成行气破泄;功在峻下逐水,荡涤积滞。
需要说明的是,制备本发明中药组合物的各原料药是按照重量份作配比,在生产时可按照相应的比例增大或减少,如大规模生产可以以千克或以吨为单位,小规模生产也可以克为单位,重量可以增大或减小,但各组成之间的原料药质量配比比例不变。
此外,本发明中药组合物可根据需要进一步制备成药学上可接受的剂型;且以上述中药组合物为活性成分制成的药物也属于本发明的保护范围。通过将上述药物组合物,直接制备或者加入药学上可接受的辅料后制备,可制成任何药学上可接受的剂型。各种剂型的药物均可以按照药学领域的常规方法制备。
第二方面,本发明提供一种中药组合物的制备方法,包括以下步骤:S1:将各原料组分进行加工处理,分别得到炮制赤小豆、炮制大戟、煨甘遂、炮制醋芫花、炮制醋荛花、炮制活大蟾蜍、炮制白芥子、炮制蜣螂、炮制蝼蛄、炮制马钱子;将轻粉研细粉,将芒硝矿物煮炼后精制,之后研细粉;S2:将加工处理后的各原料混合均匀,得到中药组合物。
优选地,加工处理具体包括以下步骤:炮制赤小豆:将赤小豆微火炒至深黄色且微有香气,研细粉;炮制大戟:将大戟切段和/或片,按照醋炙法,用陈醋浸拌,之后文火煮至醋尽,再用微火炒干,取出,晒干后研细粉;煨甘遂:在甘遂中加入麦麸且同炒至焦黄色,取出,筛去麸皮;或者,按照醋炙法处理,之后研细粉;炮制醋芫花:将芫花按醋炙法微炒至醋吸尽,研细粉;炮制醋荛花:将荛花按醋炙法微炒至醋吸尽,研细粉;炮制活大蟾蜍;将砂仁装入蟾蜍腹内,不除蟾内脏,缝口,用黄泥土封固周身,炭火煅红,候冷,研细粉;炮制白芥子:将白芥子微炒至深黄色且微有香气,研细粉;炮制蜣螂:除去蜣螂足、翅,切制后焙干,研细粉;炮制蝼蛄:除去蝼蛄翅足,焙至黄褐色用,研细粉;炮制马钱子:将砂子炒热,加入马钱子炒至呈深黄色并有皮壳鼓起后取出,筛去砂子,刮去毛,研细粉,得到马钱子粉;或者,取马钱子加水煮沸后取出,再用水浸泡,之后刮去皮毛,微晾后切成薄片,得到马钱子片,然后将麻油烧热后加入马钱子片,炒至微黄色,取出,研细粉。
优选地,炮制大戟中,每100斤大戟用陈醋30斤;煨甘遂中,每100斤甘遂用麦麸40斤;炮制醋芫花中,每100kg芫花用陈醋20kg;炮制醋荛花中,每100kg荛花用醋5kg;炮制活大蟾蜍中,每个蟾蜍装入10~20粒砂仁。
优选地,加工处理之前还包括步骤:将各原料进行除杂和/或清洗处理。
第三方面,本发明提供的中药组合物在制备治疗积水症的药物和/或药物添加剂中的应用,积水症包括癌症与非癌症引起的心包积水、胸腔积水、肝癌、肝硬化腹水、尿毒症腹水、尿闭症,该配方疗效确切;以及五脏六腑积水症,具体包括肾炎气臌胀、坐骨神经痛之急实、下肢肿胀、痛风、急性胸膜炎,痰挟死血、肺痈胸中痰水、肝气郁结、顽痰恶血凝结少阳之经脉、关节囊积液和下肢静脉血栓胀肿中的一种或多种;且尤其是脑积水症、心包积水症、胸腔积水症、肝硬化腹水症、尿毒症血透腹水症和肾炎气臌胀中的一种或多种。日服药三次、每次三粒胶囊。五天至一周内治愈。
对于一般积水、胸腹水经治疗5~7天、一个疗程后即可完全消失。不良反应:极少数患者初次服药后会有不同程度的中、下焦不适。如症状严重,可进食水果或冷糖开水,反应即可减轻消失。对于大症、重症、危症,一般经治疗7~10天,积水、脑积水、腹水、便与尿液即可完全排除消失。
用量:每服4~6粒胶囊、片剂每服2~4片。第一天恶水二便排除后、第二天每天早晚各一次服3粒胶囊药。根据病情适度加、减药量、萝卜汤调下。服药期间:请用低盐饮食,禁食生冷、辛辣、鱼及猪头肉发物;治疗期间:每日食盐不超过2克。禁用:孕妇、心力衰竭、食道静脉曲张及体极虚弱者忌服。
注意:服用本药胶囊时、不可再服用有甘草组成的药物,因甘草与大戟、甘遂相反;大戟与甘草配伍是禁忌的,属十八反之列。动物试验证明:小鼠腹腔注射大戟、甘草混合后的乙醇浸出液,其半数致死量要比单独应用大戟时小数倍,可见两者配伍时大戟的毒性增加,而且配伍的甘草愈多,毒性也愈大。此外,癌症短期不会死亡、各种急症积水症几天就会把人胀死。此外,癌症、传染病患者、脑积水、心包积水、尿毒症血透二年以上、肝癌、肝硬化腹水、排除二便极度困难的危症、腹胀满如鼓(外治)疗法:病人必须先服用本发明中药组合物之后,必定要用克民(抗癌阻隧绽0.2g)填于神阙穴内;另用芫花末0.2g放诸药于二层纱布上、盖上田螺肉一枚、点燃艾炙;或用克民阳燧锭炮烙法;在一小时内可见证二便大量排泻“立竿见影”之功效;本发明中药组合物为危症病人争取更有效治病生存时间。其中,人体各器官积水针灸或艾灸法:脾俞穴(治胀,随年壮适时灸之),肝俞穴(治胀,针灸百壮),三焦俞穴(治心腹胀满,饮食减少,小便不利,羸瘦少气),分水穴(治腹胀绕脐结痛,不能食、若是水病,尤宜灸之),神阙穴(主水肿膨胀,肠鸣如水之声,极效),石门穴(主水肿水行皮中,小便黄),足三里穴(主水肿腹胀),水沟穴(主一切水肿胀)。
进一步地,本发明用于治疗积水症的中药组合物(也称“恶水胶囊”)配合电解银四药“金玉石”合成银液翠青“银抗癌阳燧锭”,具有卓越的抗生素及灭菌作用。银作用在抗微生物中独树一帜,西医药物(西药抗生素)长期会产生耐药性及剧毒性副作用。西药抗生素平均只能对5种病菌起到作用,大多数杀灭细菌的西药抗生素不会杀灭真菌/酵母菌、寄生虫或病毒;抗真菌类的抗生素对细菌、病毒、寄生虫等无效。中医“岐黄”科学技术用纹银金玉石制成“阳燧锭”可以消灭650种不同的病原体、阳燧锭是现代世界上真正唯一的天然抗生素。银在克服西药抗生素耐药性剧毒性副作用缺陷的基础上,又广谱杀菌、无刺激、无任何交叉药物感染、银才是发挥治恶症救人的时代价值。银热传导性能迅速降低血脉的热量、预防各种疾病HPV、HIV、Leukemia有卓越的疗效。银有吸收毒性的功能,这是它变色的原因之一,因此它有卓越的消毒性能、这种变色只是表面反应、用牙膏或者药品消除。可见、“阳燧锭”银对人类健康与疾病的治疗重要性是不可忽视的。银与西药抗生素不同,“阳燧锭”银是“均等机会破坏者”它不加区别有效杀各种细菌、“G和G一菌、产芽孢菌”真菌/酵母菌、病毒、支原体与寄生虫。电解产生胶体银能够杀灭许多细菌、包括斯氏普罗威登斯菌、除“阿米卡星”外的所有抗生素都耐药的细菌银还能杀灭溶组织阿米巴原虫的胞囊、磺胺嘧啶银在中医“岐黄”之术广泛使用、用于预防焼伤感染、能够杀灭几十种细菌、72株疱疹病毒中的95%、疟原虫以及各种酵母菌包括毛霉、曲霉、黑根霉、白色念珠菌的50种不同临床分离株。极低浓度百万份之一的银液体就能杀灭各种酵母菌/真菌;包括;白色念珠菌、近平滑念珠菌、热带念珠菌、变形杆菌、光滑球拟酵母菌、黑曲霉等。2.2ppm的银液体(每百万份水、2.2份银)能杀灭草履虫。诸多传染病、恶性肿瘤的防治方法;它完全摧毁了斑疹伤寒、疟疾、霍乱和阿米巴痢疾病毒。这种家用杀菌剂是多一种银胶体。西药抗生素对病毒不起任何作用,这意味着服用任何抗生素对病毒感染没有影响。细菌的多种形式现在对大多数抗生素具有抗药性。“阳燧锭”银胶体将杀死病毒,并同时增强病人的自然免疫系统。治疗癌症病人时使用阳燧锭银。“成功取决于人体内的银含量,而失败是由于体内缺少银”。当有了银,癌细胞会分解,身体也会恢复。当没有了银的含量,癌症会加速生长…扩散…因为细胞不能去分化。人体内余留的银对免疫系统杀死病毒和细菌的能力有很大的影响。人体银缺乏是癌症存在的主要原因之一,并且正快速地增长。在矿物质补充剂中找不到金和银,因此,要采取相应的行动,人的身体必须有这些物质、否则;人们会出现老年痴呆、帕金森综合症、衰老和其他无法治疗的“疾病”。这是矿物家族中最重要的两种元素。银抗癌阳燧锭也被有效地用于治疗:痤疮、过敏、盲肠炎、风湿性关节炎、膀胱炎症、血液寄生虫和中毒、腋下和脚部的溴汗症、疖子、癌、念珠菌病、脑脊髓炎、脑膜炎、霍乱、慢性疲劳、结肠炎、结膜炎、感染引起的糖尿病、奋森氏咽峡炎、淋病、春季结膜炎、脓疱病、花斑癣,软疮,阑尾炎手术后感染,头皮和阴部的脓疱和湿疹,慢性湿疹,慢性中耳炎,颈部疥疮,口炎性腹泻,痢疾和肠道疾病,炎症、前列腺增生、膀胱炎,瘙痒,痔疮,疣,其他形式的皮炎,咽鼓管炎、习惯性口腔溃烂(包括牙槽化脓)、喉咙(包括扁桃腺炎和扁桃体炎)耳朵(包括;梅尼埃病、中枢性疾病、外周性疾病、代谢性疾病、系统性疾病)传染病败血症、白带、膀胱炎、百日咳、带状疱疹、流感、咽喉痛、产后败血症、酵母菌感染、真菌感染、病毒性胃溃疡,以及许多许多许多其他疾病。
本发明的上述技术方案相比现有技术具有以下优点:
(1)本发明提供的治疗积水症的中药组合物具有优异的抗癌排毒、肿胀喘满、热寒咳嗽、心胸痞闷、食积、水疾蛊胀、逐水消肿等功效;其解诸毒、利尿糖、降尿酸、利关窍、化痞消积、泻水逐饮;消坚破积、气滞血凝、癥瘕痞块、脘腹疼痛、胸胁胀满、横痃、瘰疬、痰核、流注、小肠痈、类风湿关节变形之中期患者、坐骨神经痛之急实。下肢肿胀、急性胸膜炎,痰挟死血、肺痈胸中痰水、肝气郁结、顽痰恶血凝结少阳之经脉、关节囊积液、下肢静脉血栓胀肿、乳腺囊性增生、多发性脓肿、骨髓炎。泻肺性峻利,善逐水邪痰涎,泻湿热胀满全身水肿、胸肋膜积水、大腹疝瘕,腹满,面目浮肿,留饮宿食,破症坚积聚,利水谷道。对痢疾杆菌、伤寒杆菌、霍乱弧菌、大肠杆菌、绿脓杆菌、葡萄球菌、链球菌、肺炎双球菌、白喉杆菌、炭疽杆菌及皮肤真菌有抗菌作用、腮腺炎,乳腺炎,淋巴腺炎。下五水,散膀胱留热,皮中痞,热气肿满。能泻十二种水疾。治心腹坚满,下水,去痰水,主皮肤浮肿。泻肾经及隧道水湿,脚气,阴囊肿坠,痰迷癫痫,噎膈痞塞。妇人积年血气癥块结痛、一切病毒菌、水盅胀满、干呕胁痛、子宫结块,月经不通、卒得咳嗽、水病通身微肿,腹大,食饮不消、时行毒病、热积聚胸中,烦乱欲死精神分裂症、躁抑症、神经官能症、癫痫。颈淋巴结核、结核性腹膜炎、慢性纤维性空洞性肺结核合并胸膜炎。
(2)本发明提供的治疗积水症的中药组合物功能主治:用于结核菌、肺炎双球菌、链球菌、脑膜炎球菌、淋球菌。组织胞浆菌、放线菌、球霉菌、曲菌、囊球菌。支气管癌、传染病肺结核心包积水、胸腺癌、黑色素癌、淋巴瘤、白血病。CoxsackieB、A,Echo心水病毒、结核菌、肺炎双球菌、链球菌、脑膜炎球菌、淋球菌。流感病毒;传染性单核细胞增多症。组织胞浆菌、放线菌、球霉菌、曲菌、囊球菌、肺癌、乳腺癌、淋巴瘤、纵隔肿瘤类风湿性关节炎、系统性红斑狼疮、硬皮病,代谢病尿毒症、痛风、新液性水肿、胆固醇性心包炎者糜性心包炎。恶性肿瘤或非肿瘤引起、脑积液、胸积水、心包积水、肝癌、肝硬化腹水、尿毒症腹水、尿闭症、中满腹胀,喘嗽淋閟;水湿肿满,湿热肠垢沉积变生疾病,腹满实痛。痰饮;咳逆上气;水肿;喉中肿满;癥瘕痃癖。行气消积。理脾和胃,舒气宽胸。肾气郁臌胀,胸腹胀满,气急难卧,二便不畅,神倦肢瘦,肚腹单胀,无论新久。大腹胀气,小儿面黄肌瘦,肚腹胀满等症。胸腹胀满不适,按之仍觉柔软,伴有气逆,嗳气等症状。腹大、青筋显露,肤色苍黄,四肢消瘦,小儿疳积,慢性气管炎。抗肿瘤强心利尿,镇痛。治水肿腹水痈肿、阴疮、阴蚀、疽疠、恶疮、一切五疳八痢,肿毒,破伤风病,脱肛、大肠痔疾。
本发明的附加方面和优点将在下面的描述中部分给出,部分将从下面的描述中变得明显,或通过本发明的实践了解到。
附图说明
图1为本发明实施例中肝硬化腹水的临床照片;
图2为本发明实施例中脑水肿的电镜图;
图3为本发明实施例中脑积水的电镜图;
图4为本发明实施例中尿毒症血透腹水的临床照片;
图5为本发明实施例中心包积水的示意图。
具体实施方式
下面将对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚的说明本发明的技术方案,因此只作为实例,而不能以此来限制本发明的保护范围。
下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的试验材料,如无特殊说明,均为自常规试剂商店购买得到的。以下实施例中的定量试验,均设置三次重复实验,数据为三次重复实验的平均值或平均值±标准差。
下述实施例中所用的赤小豆、大戟、甘遂、芫花、荛花、蟾蜍、白芥子、蜣螂、蝼蛄和马钱子均符合《中国药典》正文各药材项下的有关规定。投料前,通过鉴定,各味药材实物与名称相符,质量符合标准。下面结合具体实施方式进行说明:
本发明提供一种用于治疗积水症的中药组合物,原料组分按重量份计,包括:赤小豆1~100重量份、大戟1~100重量份、甘遂1~100重量份、芫花1~100重量份、荛花1~100重量份、蟾蜍0.01~10重量份、白芥子1~100重量份、蜣螂1~100重量份、蝼蛄1~100重量份、马钱子1~100重量份、轻粉1~100重量份和芒硝1~100重量份。
另外,针对上述中药组合物,申请人专门设计了制备方法,包括以下步骤:
S1:将各原料组分进行加工处理,具体地:
炮制赤小豆:原药簸尽杂质,微火炒至深黄色且微有香气,研细粉。炮制大戟:将大戟切段和/或片,按照醋炙法,用陈醋浸拌大戟,文火煮至醋尽,再用微火炒干,取出,晒干后研细粉;其中,每100斤大戟用陈醋30斤。
煨甘遂:取净甘遂,加入麦麸且同炒至焦黄色,取出,筛去麸皮;或者,按照醋炙法处理,之后研细粉;其中,每100斤甘遂用麦麸40斤。
炮制醋芫花:取净芫花,按照醋炙法微炒至醋吸尽,研细粉;其中,每100kg芫花用陈醋20kg。
炮制醋荛花:取净荛花,按照醋炙法微炒至醋吸尽,研细粉;其中,每100kg荛花用醋5kg。
炮制活大蟾蜍;将砂仁装入蟾蜍腹内,不除蟾内脏,缝口,用黄泥土封固周身,炭火煅红,候冷,研细粉;其中,每个蟾蜍装入10~20粒砂仁。
炮制白芥子:原药簸尽杂质,微炒至深黄色且微有香气,研细粉。
炮制蜣螂:去蜣螂杂质,去足、翅,切制后焙干,研细粉。
炮制蝼蛄:拣净蝼蛄杂质,除去翅足,焙至黄褐色用,研细粉。
炮制马钱子:将砂子炒热,加入拣净的马钱子,炒至呈深黄色并有皮壳鼓起后取出,筛去砂子,刮去毛,研细粉,得到马钱子粉;或者,取拣净的马钱子,加水煮沸后取出,再用水浸泡,之后刮去皮毛,微晾,切成薄片,得到马钱子片,然后将麻油烧热后加入马钱子片,炒至微黄色,取出,研细粉。
将轻粉选用氯化亚汞结晶,研细粉。
芒硝:将芒硝矿物含水硫酸钠、经煮炼而得精制结晶Na2SO4·10H2O,之后研细粉。
S2:将加工处理后的各原料混合均匀,得到中药组合物。
下面结合具体实施方式进行说明:
实施例一
本实施例提供一种用于治疗积水症的中药组合物,原料组分按重量份计,包括:赤小豆60重量份、大戟30重量份、甘遂40重量份、芫花20重量份、荛花50重量份、活大蟾蜍1/2重量份、白芥子60重量份、蜣螂20重量份、蝼蛄30重量份、马钱子15重量份、轻粉20重量份和芒硝20重量份。
按上述原料组分,制备本发明的中药组合物:
S1:将各原料组分进行加工处理,具体地:炮制赤小豆:原药簸尽杂质,微火炒至深黄色且微有香气,研细粉。炮制大戟:将大戟切段和/或片,按照醋炙法,用陈醋浸拌大戟,文火煮至醋尽,再用微火炒干,取出,晒干后研细粉;其中,每100斤大戟用陈醋30斤。煨甘遂:取净甘遂,加入麦麸且同炒至焦黄色,取出,筛去麸皮;或者,按照醋炙法处理,之后研细粉;其中,每100斤甘遂用麦麸40斤。炮制醋芫花:取净芫花,按照醋炙法微炒至醋吸尽,研细粉;其中,每100kg芫花用陈醋20kg。炮制醋荛花:取净荛花,按照醋炙法微炒至醋吸尽,研细粉;其中,每100kg荛花用醋5kg。炮制活大蟾蜍;将砂仁装入蟾蜍腹内,不除蟾内脏,缝口,用黄泥土封固周身,炭火煅红,候冷,研细粉;其中,每个蟾蜍装入10~20粒砂仁。炮制白芥子:原药簸尽杂质,微炒至深黄色且微有香气,研细粉。炮制蜣螂:去蜣螂杂质,去足、翅,切制后焙干,研细粉。炮制蝼蛄:拣净蝼蛄杂质,除去翅足,焙至黄褐色用,研细粉。炮制马钱子:将砂子炒热,加入拣净的马钱子,炒至呈深黄色并有皮壳鼓起后取出,筛去砂子,刮去毛,研细粉,得到马钱子粉;或者,取拣净的马钱子,加水煮沸后取出,再用水浸泡,之后刮去皮毛,微晾,切成薄片,得到马钱子片,然后将麻油烧热后加入马钱子片,炒至微黄色,取出,研细粉。将轻粉选用氯化亚汞结晶,研细粉。芒硝:将芒硝矿物含水硫酸钠、经煮炼而得精制结晶Na2SO4·10H2O,之后研细粉。
S2:将加工处理后的各原料混合均匀,得到中药组合物。
实施例二
本实施例提供一种用于治疗积水症的中药组合物,原料组分按重量份计,包括:赤小豆50重量份、大戟50重量份、甘遂20重量份、芫花40重量份、荛花30重量份、活大蟾蜍1/2重量份、白芥子50重量份、蜣螂30重量份、蝼蛄20重量份、马钱子20重量份、轻粉10重量份和芒硝30重量份。
按上述原料组分,制备本发明的中药组合物:
S1:将各原料组分进行加工处理,具体地:炮制赤小豆:原药簸尽杂质,微火炒至深黄色且微有香气,研细粉。炮制大戟:将大戟切段和/或片,按照醋炙法,用陈醋浸拌大戟,文火煮至醋尽,再用微火炒干,取出,晒干后研细粉;其中,每100斤大戟用陈醋30斤。煨甘遂:取净甘遂,加入麦麸且同炒至焦黄色,取出,筛去麸皮;或者,按照醋炙法处理,之后研细粉;其中,每100斤甘遂用麦麸40斤。炮制醋芫花:取净芫花,按照醋炙法微炒至醋吸尽,研细粉;其中,每100kg芫花用陈醋20kg。炮制醋荛花:取净荛花,按照醋炙法微炒至醋吸尽,研细粉;其中,每100kg荛花用醋5kg。炮制活大蟾蜍;将砂仁装入蟾蜍腹内,不除蟾内脏,缝口,用黄泥土封固周身,炭火煅红,候冷,研细粉;其中,每个蟾蜍装入10~20粒砂仁。炮制白芥子:原药簸尽杂质,微炒至深黄色且微有香气,研细粉。炮制蜣螂:去蜣螂杂质,去足、翅,切制后焙干,研细粉。炮制蝼蛄:拣净蝼蛄杂质,除去翅足,焙至黄褐色用,研细粉。炮制马钱子:将砂子炒热,加入拣净的马钱子,炒至呈深黄色并有皮壳鼓起后取出,筛去砂子,刮去毛,研细粉,得到马钱子粉;或者,取拣净的马钱子,加水煮沸后取出,再用水浸泡,之后刮去皮毛,微晾,切成薄片,得到马钱子片,然后将麻油烧热后加入马钱子片,炒至微黄色,取出,研细粉。将轻粉选用氯化亚汞结晶,研细粉。芒硝:将芒硝矿物含水硫酸钠、经煮炼而得精制结晶Na2SO4·10H2O,之后研细粉。
S2:将加工处理后的各原料混合均匀,得到中药组合物。
针对本发明的中药组合物,申请人进行了下述临床实验:
1、10例慢性纤维性空洞性肺结核合并胸膜炎,胸腔积液。10天内西医抽胸水4次,经加用马前子药蛋一个疗程后,胸水全部吸收。肺门淋巴结核,使用药蛋后也有明显效果。马钱子碱能完全抑制流感嗜血杆菌,肺炎双球菌,甲型链球菌和卡他球菌的生长、抗许兰氏黄癣菌,奥杜盎氏小芽胞癣菌。此方是中华“岐黄”之术“破泄痰涎”之剂。
2、治疗肝癌、肝腹水
肝之治有数种:水衰而木无以生者,乙癸同源;土衰而木无以植者,缓肝培土是也;本经血虚有火者;血虚无火者。至于补火之法,亦下同乎肾;而泻火之治,则上类乎心。左金丸独用黄连为君,从实则泻子之法,以直折其上炎之势;吴茱萸从类相求,引热下行,并以辛温开其郁结,惩其杆格,故以为佐。然必木气实,而土不虚者,庶可相宜,必须采取祛癌毒疗法;最重要法则是补虐扶正。肝硬化腹水的临床照片如图1所示。
临床应用案例:吴某,福建人,肝癌、肝硬化腹水涨满,曾于17年三月确诊;四月先后到香港、上海著名大医院治癌、肝硬化腹水、换肝脏。为此,香港和上海相应医院都采取无效利汗药“穿刺抽腹水”肝硬化腹水病人没有任何进展,11月12日病人放弃换肝。之后服用本发明恶水胶囊1.5g,同时实施(阳隧锭0.3g)填于神阙穴内盖姜片实施艾灸30分钟。实施阳燧锭炮烙法;肝俞穴、足三里穴、水疾蛊胀、逐水消肿。解诸毒、利尿糖、降尿酸、病人一小时内开始大量排泻二便。10天内病人恢复二便正常、申请人医治肝癌、肝硬化病人腹水涨满、“并发症”盼望病人得到现代医学有效治愈肝癌、肝硬化、早日恢复健康创造宝贵治癌时间。
3、治疗脑积水
《灵枢·海论》曰:“脑为髓之海”。肾者主藏精、精能生髓、髓汇于脑、若肾虚则髓海不足、故用补肾益髓之法。热邪在骨髓,而脑为髓海,故热气从骨髓流入于脑,则身体发黄,头脑痛,眉疼。脑水肿和脑积水的电镜图如图2和图3。
临床应用案例:姜某,男,5岁,恶性胶质瘤三级并伴有大量脑积水,17年4月医院诊断后需实施颅内分流和颅外分流,颅内分流有脑室-小脑延髓池引流术、三脑室造瘘术。后服用本发明恶水胶囊三粒1g,实施头皮针炙;百会、四聪穴,(抗癌阳隧锭0.2g)放于百会穴、内盖姜片实施艾灸30分钟。在病人神阙穴、投放抗癌银翠绿青0.2g、实施艾灸20分钟。阳燧锭炮烙法;石门穴、水沟穴、三焦俞、肾俞、随着肺的呼吸运动,治理和调节着全身的气机、(气的升降出入运动)辅助心脏,推动和调节血液的运行>肺的宣发和肃降,治理和调节津液的输布、运行和排泄。水疾蛊胀、逐水消肿毒。幼童病人在一小时内开始排泻二便、经过几天精心治疗脑积水得到全部及时排除。
4、治疗肺癌胸水
肺是心脏的保护器官、对津液的生成、输布与排泄过程做了明确的概括;如;“脏腑与人体水液代谢”。胃液、肠液、唾液、关节液,习惯上也包括代谢产物中的尿、汗、泪。津液以水分为主体,含有大量的营养物质,津液是构成人体维持生命活动的基本物质、人体依赖脾脏的转输“散精”功能与肺的宣发“输精于皮毛”功能。肺的肃降作用“通调水道”将津液下输于肾和膀胱。在肾的蒸腾气化作用下、以三焦为通道、布散于全身而环流不息。津液亏必定会导致血瘀、血液与津液之间存在着极其同源密切关系。血液与津液生成都源于水谷之精气、津液渗注于血脉中、成为血液的组成部分。
临床应用案例:严某,浙江人,肺恶性胸膜间皮瘤,胸膜大量积水。病人10天胸膜积水接受三次穿刺抽水;后服用本发明恶水胶囊1~1.5g排除积水,病人有大量积水。病人服用恶水胶囊1.5g,实施阳隧锭0.2g,填于胸膜腔积水位置、盖姜片实施艾灸20分钟。针灸肺俞穴、水沟穴,一小时内病人开始大量排泻二便。申请人为肺恶性胸膜间皮瘤病人争取治愈“并发症”早日恢复健康创造宝贵治疗时间。
5、治疗脑积水血透尿毒症腹水
中医学治水哲理;急则治其表、缓则治其本、实者泻之、虚者补之、标本兼治。先天靠肾、后天靠脾、脾主运化、通过恢复脾脏运化功能;键脾化湿、理气行水;清热除湿、利尿泄浊、温肾暖脾、化气行水、疏肝解瘀。恢复肝、脾、肾功能为主;必须做到临床症状消除、脏腑功能恢复、提高免疫功能。恶性脑积水、胸腔积水、心包积水;中医采用健脾利湿;“培土生金”和解宣利、泻肺袪饮、理气活络、养阴清热、发表化饮、温肺化饮、泻肺逐饮、补虚清热、行水散结;温补脾肾、以化水饮。治标“发汗、利水、功逐”权宜之法;治本善后“健脾、温肾”正治法;通过恢复肺、脾、肾通调、转输、蒸化水液功能、最终达到康复。尿毒症血透腹水的临床照片如图4所示。
临床应用案例:蔡某,晋江人,尿毒症血透腹水涨满。服用本发明恶水胶囊1.5g(抗癌阳隧锭0.2g)填于神阙穴内盖姜片实施艾灸30分钟。阳燧锭炮烙法;针炙;分水穴、水沟穴、消水疾蛊胀、逐水消涨肿。病人蔡先生在一小时内开始大量排泻二便、中医学有实力排除患者尿毒症血透腹水。病人在10小时后二便恢复正常、申请人运用“岐黄”之术、希望尿毒症病人后续治疗“并发症”早日恢复健康创造宝贵治疗时间。
6、治疗心包积水
《素问·灵兰秘典论》曰:“心者,君主之官,神明出焉。”心在五行属火,方位属南,为阳,人君之位。《易》以离为火,居太阳之位,人君之象。“心为君主之官”,或盖源于此。心包积水的示意图如图5所示。心的生理功能是藏神~外邪侵袭的时候,先是心包代心受邪,如果心脏器受邪了,就会出现心伤而神去则人死。所以,心不能受邪。关于手少阴独无输穴的解释:“其外经病而脏不病,故独取其经于掌后锐骨之端。
临床应用案例:许某,晋江人,10多年前患肺结核没有治愈。17年2月肺结核严重复发、右肺CT检测已经全部萎缩。心衰、心包积水、胸水、下肢肿、病情危及生命。医院建议;病人必须做剑突下心包引流、心包穿刺、心包开窗的方法;实施清除心包积液,有可能减少心包积液复发的可能性、防止晚期心包缩窄。之后服用恶水胶囊1.5g同时用(抗癌阳隧锭0.2g)分别填于肺俞穴、心俞穴盖姜片实施艾灸与针炙30分钟。同时实施阳燧锭炮烙法;三焦俞穴、水沟穴、神门穴、针灸;五输穴、少冲、少府、神门、灵道、少海、内关穴、巨阙穴、郄门穴排除水疾蛊胀、逐水消肿、病人在中医“岐黄”医技学术措施完成后、开始大量排泻二便。有90%积水症病人都能取得“立竿见影”疗效。申请人盼望着为“并发症”病人早日治愈后期肺结核恢复健康、创造宝贵治疗时间。
当然,除了实施例一和实施例二列举的情况,其他原料组分的种类和重量百分比、制备过程中的条件和参数等也是可以的。
本发明治疗积水症的中药组合物选用含有天然活性成分的中药药材,组方配比科学,具有优异的抗癌排毒、肿胀喘满、热寒咳嗽、心胸痞闷、食积、水疾蛊胀、逐水消肿等功效,能够有效用于治疗脑积水症、心包积水症、胸腔积水症、肝硬化腹水症、尿毒症血透腹水症和肾炎气臌胀等症。
在本说明书的描述中,参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不必须针对的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任一个或多个实施例或示例中以合适的方式结合。此外,在不相互矛盾的情况下,本领域的技术人员可以将本说明书中描述的不同实施例或示例以及不同实施例或示例的特征进行结合和组合。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (10)
1.一种用于治疗积水症的中药组合物,其特征在于,原料组分包括:
赤小豆、大戟、甘遂、芫花、荛花、蟾蜍、白芥子、蜣螂、蝼蛄、马钱子、轻粉和芒硝中的一种或多种。
2.根据权利要求1所述的用于治疗积水症的中药组合物,其特征在于,原料组分按重量份计,包括:
赤小豆1~100重量份、大戟1~100重量份、甘遂1~100重量份、芫花1~100重量份、荛花1~100重量份、蟾蜍0.01~10重量份、白芥子1~100重量份、蜣螂1~100重量份、蝼蛄1~100重量份、马钱子1~100重量份、轻粉1~100重量份和芒硝1~100重量份。
3.根据权利要求2所述的用于治疗积水症的中药组合物,其特征在于,由下述原料制备而成:
赤小豆20~80重量份、大戟20~60重量份、甘遂10~50重量份、芫花10~50重量份、荛花20~60重量份、蟾蜍1/3~2/3重量份、白芥子40~70重量份、蜣螂10~40重量份、蝼蛄10~40重量份、马钱子5~30重量份、轻粉5~30重量份和芒硝10~50重量份。
4.根据权利要求1~3任一项所述的用于治疗积水症的中药组合物,其特征在于:
所述轻粉选用氯化亚汞结晶;所述芒硝的主要成分为含水硫酸钠,且具体为Na2SO4·10H2O;所述蟾蜍选用活大蟾蜍。
5.根据权利要求1~3任一项所述的用于治疗积水症的中药组合物,其特征在于:
所述中药组合物呈胶囊粒或糖衣片状;
优选地,胶囊粒的含量为0.35g;糖衣片的含量为0.5g。
6.权利要求1~5任一项所述中药组合物的制备方法,其特征在于,包括以下步骤:
S1:将各原料组分进行加工处理,分别得到炮制赤小豆、炮制大戟、煨甘遂、炮制醋芫花、炮制醋荛花、炮制活大蟾蜍、炮制白芥子、炮制蜣螂、炮制蝼蛄、炮制马钱子;将轻粉研细粉,将芒硝矿物煮炼后精制,之后研细粉;
S2:将所述加工处理后的各原料混合均匀,得到所述中药组合物。
7.根据权利要求6所述中药组合物的制备方法,其特征在于:
所述加工处理具体包括以下步骤:
炮制赤小豆:将赤小豆微火炒至深黄色且微有香气,研细粉;
炮制大戟:将大戟切段和/或片,按照醋炙法,用陈醋浸拌,之后文火煮至醋尽,再用微火炒干,取出,晒干后研细粉;
煨甘遂:在甘遂中加入麦麸且同炒至焦黄色,取出,筛去麸皮;或者,按照醋炙法处理,之后研细粉;
炮制醋芫花:将芫花按醋炙法微炒至醋吸尽,研细粉;
炮制醋荛花:将荛花按醋炙法微炒至醋吸尽,研细粉;
炮制活大蟾蜍;将砂仁装入蟾蜍腹内,不除蟾内脏,缝口,用黄泥土封固周身,炭火煅红,候冷,研细粉;
炮制白芥子:将白芥子微炒至深黄色且微有香气,研细粉;
炮制蜣螂:除去蜣螂足、翅,切制后焙干,研细粉;
炮制蝼蛄:除去蝼蛄翅足,焙至黄褐色用,研细粉;
炮制马钱子:将砂子炒热,加入马钱子炒至呈深黄色并有皮壳鼓起后取出,筛去砂子,刮去毛,研细粉,得到马钱子粉;或者,取马钱子加水煮沸后取出,再用水浸泡,之后刮去皮毛,微晾后切成薄片,得到马钱子片,然后将麻油烧热后加入马钱子片,炒至微黄色,取出,研细粉。
8.根据权利要求7所述中药组合物的制备方法,其特征在于:
所述炮制大戟中,每100斤大戟用陈醋30斤;
所述煨甘遂中,每100斤甘遂用麦麸40斤;
所述炮制醋芫花中,每100kg芫花用陈醋20kg;
所述炮制醋荛花中,每100kg荛花用醋5kg;
所述炮制活大蟾蜍中,每个蟾蜍装入10~20粒砂仁。
9.根据权利要求7所述中药组合物的制备方法,其特征在于:
所述加工处理之前还包括步骤:将各原料进行除杂和/或清洗处理。
10.权利要求1~5任一项所述中药组合物在制备治疗积水症的药物和/或药物添加剂中的应用,其特征在于:
所述积水症包括癌症与非癌症引起的心包积水、胸腔积水、肝癌、肝硬化腹水、尿毒症腹水、尿闭症,以及五脏六腑积水症,具体包括肾炎气臌胀、坐骨神经痛之急实、下肢肿胀、痛风、急性胸膜炎,痰挟死血、肺痈胸中痰水、肝气郁结、顽痰恶血凝结少阳之经脉、关节囊积液和下肢静脉血栓胀肿中的一种或多种;且尤其是脑积水症、心包积水症、胸腔积水症、肝硬化腹水症、尿毒症血透腹水症和肾炎气臌胀中的一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811514368.4A CN109364157A (zh) | 2018-12-12 | 2018-12-12 | 用于治疗积水症的中药组合物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811514368.4A CN109364157A (zh) | 2018-12-12 | 2018-12-12 | 用于治疗积水症的中药组合物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109364157A true CN109364157A (zh) | 2019-02-22 |
Family
ID=65374412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811514368.4A Pending CN109364157A (zh) | 2018-12-12 | 2018-12-12 | 用于治疗积水症的中药组合物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109364157A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481889A (zh) * | 2003-07-01 | 2004-03-17 | 冯春和 | 芫甘泻水丸 |
CN101940647A (zh) * | 2010-09-10 | 2011-01-12 | 重庆市南川区金佛山中药材品种培育研究所 | 治疗臌胀(实证)的中草药 |
CN102908480A (zh) * | 2012-09-20 | 2013-02-06 | 李承平 | 一组芫花行气利水片 |
KR20150083328A (ko) * | 2014-01-09 | 2015-07-17 | 한국생명공학연구원 | 두메닥나무 추출물 또는 이의 분획물을 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
CN108619326A (zh) * | 2018-08-13 | 2018-10-09 | 佛山瑞箭体育器材有限公司 | 一种可以逐水消肿的中药丸剂 |
-
2018
- 2018-12-12 CN CN201811514368.4A patent/CN109364157A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481889A (zh) * | 2003-07-01 | 2004-03-17 | 冯春和 | 芫甘泻水丸 |
CN101940647A (zh) * | 2010-09-10 | 2011-01-12 | 重庆市南川区金佛山中药材品种培育研究所 | 治疗臌胀(实证)的中草药 |
CN102908480A (zh) * | 2012-09-20 | 2013-02-06 | 李承平 | 一组芫花行气利水片 |
KR20150083328A (ko) * | 2014-01-09 | 2015-07-17 | 한국생명공학연구원 | 두메닥나무 추출물 또는 이의 분획물을 포함하는 염증성 질환의 예방 또는 치료용 조성물 |
CN108619326A (zh) * | 2018-08-13 | 2018-10-09 | 佛山瑞箭体育器材有限公司 | 一种可以逐水消肿的中药丸剂 |
Non-Patent Citations (1)
Title |
---|
王揆方: "中药治疗癌性胸水2例", 《江西中医药》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103893731A (zh) | 治疗食管癌、胃癌、肝癌及脑肿瘤的中药物及其制备方法 | |
CN105535495B (zh) | 一种培元固本治疗食管癌的中药组合物及制备方法 | |
CN103495072B (zh) | 一种治疗支气管扩张病的中药组合物及其制备方法 | |
CN102872362B (zh) | 一种治疗慢性胆囊炎的中药 | |
CN104288255A (zh) | 治疗重症急性胰腺炎的中药制剂 | |
CN104474225B (zh) | 一种治疗病毒性心肌炎的药物及制备方法 | |
CN109364157A (zh) | 用于治疗积水症的中药组合物及其制备方法与应用 | |
CN103919858B (zh) | 一种穴位外用消肿止痛、调节内分泌的外涂药物及其制备方法 | |
CN106692889A (zh) | 一种治疗甲状腺肿瘤的药物及其制备方法 | |
CN108721540A (zh) | 治疗肝癌六种情况的中药配方 | |
CN106109928A (zh) | 一种治疗食道炎的药物及制备方法 | |
CN106421573A (zh) | 一种治疗咳嗽的药物及其制备方法 | |
CN104971210A (zh) | 治疗脚癣的外洗剂及其制备方法 | |
CN105999059A (zh) | 一种天然植物类抗癌药物组合物、制剂及其制备方法 | |
CN104984305B (zh) | 一种治疗慢性胆囊炎的中药组合物 | |
CN104840743A (zh) | 一种治疗血气胸的药物及其制备方法 | |
CN104666659A (zh) | 一种治疗脂肪肝的中药制剂及制备方法 | |
CN105641362A (zh) | 一种治疗真菌性食管炎的中药 | |
CN108619452A (zh) | 一种治疗肿瘤的中药组合物以及循经透化疗法 | |
CN108355025A (zh) | 一种治疗血栓性外痔的中药熏洗药剂及其制备方法 | |
CN108272954A (zh) | 一种治疗乳痈的药物及其制备方法 | |
CN103055271A (zh) | 一种用于治疗慢性胃炎的药物及制备方法 | |
CN105878604A (zh) | 一种天然植物矿物复合抗癌药物组合物、制剂及其制备方法 | |
CN106822854A (zh) | 一种治疗胆道蛔虫病的药物及其制备方法 | |
CN106237151A (zh) | 一种治疗咽喉炎的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190222 |